Eli Lilly and Co. has expanded its immuno-oncology collaboration with Merck to add a new study of Lilly’s LARTRUVO (olaratumab) with KEYTRUDA (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS). Lilly will conduct the Phase I study, which is expected to begin mid-2017. Financial details were not disclosed. The FDA recently granted accelerated approval for LARTRUVO (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the ...